What are the guidelines for initiating, monitoring, and weaning continuous positive airway pressure (CPAP) in a spontaneously breathing preterm infant with respiratory distress, including criteria for CPAP failure, surfactant administration, transition to high‑flow nasal cannula, and adjunctive therapies?

Additional Key Points on CPAP Management in Preterm Infants

Start CPAP immediately after birth in preterm infants <30 weeks' gestation with spontaneous breathing, then give selective surfactant only if they fail CPAP—this approach reduces bronchopulmonary dysplasia and death compared to routine intubation with prophylactic surfactant. 1

Surfactant Administration Strategy

The "CPAP-first with selective surfactant" approach is superior to routine prophylactic surfactant. Early initiation of CPAP with subsequent selective surfactant administration in extremely preterm infants results in lower rates of BPD/death when compared with prophylactic surfactant therapy (Level of Evidence 1) 1.

Specific Criteria for Surfactant Administration

While the guidelines strongly recommend selective surfactant, the exact FiO2 threshold for surfactant administration remains heterogeneous across studies 2. However, practical application suggests:

• For infants <30 weeks requiring mechanical ventilation due to severe RDS, give surfactant after initial stabilization (Strong Recommendation) 1
• Early rescue surfactant (<2 hours of age) decreases mortality, air leak, and chronic lung disease 1
• A composite clinical score incorporating gestation <32 weeks, no antenatal corticosteroids, hypothermia at admission, Apgar score <3 at 1 minute, and Silverman score >2 at 2 hours may help predict surfactant need 3

CPAP Initiation Parameters

Use PEEP during initial ventilation of premature newborns in the delivery room (weak recommendation, low-quality evidence) 4. For spontaneously breathing preterm infants with respiratory distress:

• CPAP is preferred over intubation and positive-pressure ventilation (weak recommendation, moderate-certainty evidence) 5
• Start within the first 15 minutes of life 5
• CPAP reduces bronchopulmonary dysplasia and the combined outcome of death/BPD 5

Important Caveat for Term/Late Preterm Infants

For late preterm and term infants with respiratory distress, there is insufficient evidence to recommend routine CPAP use 5. One observational study suggested no harm and possible benefit from avoiding CPAP in term/late preterm infants with respiratory distress who are reaching target oxygen saturations 5.

Weaning from CPAP

Gradual decrease of CPAP pressure is more physiological and better tolerated than cycling-off CPAP 6. Key points:

• Infants are ready to wean when stable on low CPAP pressure with minimal or no oxygen requirement 6
• Cycling-off CPAP (graded time-off) increases duration of CPAP and hospital stay without beneficial effect on weaning success—avoid this method 6
• The optimal weaning strategy remains undetermined, but gradual pressure reduction is preferred over abrupt discontinuation 6

Transition to High-Flow Nasal Cannula

HFNC is an effective alternative to CPAP after extubation, but CPAP is preferred as primary respiratory support 7. This means:

• Use CPAP first for respiratory distress syndrome
• HFNC can be used as a step-down after successful CPAP weaning or post-extubation
• HFNC should not replace CPAP as initial noninvasive support in preterm infants with RDS 7

Adjunctive Therapies

Antenatal steroids and postnatal surfactant independently and additively reduce mortality, RDS severity, and air leaks (Level of Evidence 2) 1. This synergistic effect is critical:

• Antenatal steroids reduce mortality (RR 0.62), RDS (RR 0.65), and surfactant use (RR 0.45) 1
• The benefit is most consistent in infants born 28-34 weeks' gestation 1
• For extremely preterm infants ≤27 weeks, antenatal steroids don't reduce RDS incidence but significantly lower death or neurodevelopmental impairment at 18-22 months 1

Critical Pitfalls to Avoid

• Do not use sustained inflations >5 seconds routinely in preterm infants receiving positive-pressure ventilation (weak recommendation, low-certainty evidence) 5
• Ensure personnel administering surfactant have technical expertise—inexperienced providers should wait for transport teams 1
• Rescue surfactant may be considered for secondary surfactant deficiency (pulmonary hemorrhage, meconium aspiration syndrome, sepsis/pneumonia) but not for congenital diaphragmatic hernia 1

Monitoring Considerations

Quantitative lung ultrasound is increasingly supported to guide surfactant timing and re-treatment decisions 8, though this represents an emerging rather than established standard. Traditional monitoring includes clinical assessment of work of breathing, oxygen requirements, and blood gas analysis.